2009 MS Research Update
August 13, 2009
Based on the positive response to the "MS Research Updates" appearing in the Summer 2007 and 2008 issues of The Motivator, this article incorporates new information about the six approved disease-modifying therapies (DMTs), as well as experimental drugs currently being studied for the treatment of MS. Highlights and recent research results are provided for each drug. This is not a complete list and not all studies and their results are included. Initial study results should be considered preliminary, as additional studies and/or evaluations may be needed.
This information is based on a wide range of sources, including the extensive journal literature on MS and its management, a review of ongoing clinical trials, and papers presented at major national and international conferences. These include the American Academy of Neurology (AAN), the Consortium of Multiple Sclerosis Centers (CMSC), and the American and European Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS and ECTRIMS).
For an overview of MS terminology, evaluative procedures, clinical trials, and treatments please see the "Health and Wellness" column from the Summer 2007 issue of The Motivator.
Please note that this article does not include medications for managing the symptoms of MS. Treatments for symptom management are the subject of an article in the Winter/Spring 2009 issue of The Motivator.
Editor's note: MSAA does not endorse or recommend any specific products or therapies. Readers are advised to consult their physician before making any changes to their medication, diet, exercise, or other regimen.
FDA-Approved Medications
- Avonex® (interferon beta-1a)
- Betaseron® (interferon beta-1b)
- Rebif® (interferon beta-1a)
- Copaxone® (glatiramer acetate)
- Tysabri® (natalizumab)
- Novantrone® (mitoxantrone)
Experimental Oral Medications
- Cladribine
- Fingolimod (FTY720)
- BG00012 (BG 12; fumarate; fumaric acid esther)
- Laquinimod
- Teriflunomide
- Statins
Experimental Monoclonal Antibody Medications
Other Therapies Being Studied
**Please note this article appears in the Summer 2009 issue of The Motivator. Anyone wishing to receive a free copy of The Motivator may call MSAA's bilingual Helpline at (800) 532-7667. Helpline consultants and information about MSAA's programs are also available through this number.
All media inquires should be addressed to Amanda Bednar, MSAA Public Relations Manager, at (800) 532-7667, extension 122 or via email: abednar@msassociation.org.
Written by Dr. Diana M. Schneider
Reviewed by Dr. Jack Burks, MSAA Chief Medical Officer
Edited by Susan Wells Courtney, MSAA Senior Writer and Creative Director
